Health care special purpose acquisition companies in 2020-2021 represented a temporary market inefficiency that enabled weaker companies to bypass traditional due diligence and ultimately led to failures.
|Articles|March 17, 2010
Supplements and Featured Publications
- Issues in Improving the Treatment of Anemia: Negotiating the Shifting Regulatory and Clinical Landsc
- Volume 16
- Issue 3 Suppl
Posttest: Issues in Improving the Treatment of Anemia: Negotiating the Shifting Regulatory and Clinical Landscapes
Advertisement
Instructions
After reading “Issues in Improving the Treatment of Anemia: Negotiating the Shifting Regulatory and Clinical Landscapes,” complete the program evaluation and select the 1 best answer to each of the posttest questions.
A statement of continuing education hours will be provided to those physicians and pharmacists who successfully complete and return the answer form and program evaluation and receive a passing grade of 70% or higher.
Articles in this issue
Advertisement
Related to this article
Machine learning prediction of procalcitonin positivity using inexpensive routine laboratory tests may reduce procalcitonin test volume and support diagnostic stewardship.
After Pennsylvania began rewarding Medicaid managed care plans for increasing well-child visits among Black infants, rates did not change significantly overall but varied by region.
Greater 340B activity—measured by county-level hospital child sites and contract pharmacy arrangements—was associated with significantly higher county-level total and out-of-pocket health care spending.
The associate editor of Evidence-Based Oncology says the turnover that will follow this week's midterm election calls for renewed engagement from community oncology leaders with members of Congress, due to pressing reimbursement issues.
Medigap Plan F enrollment has declined since it was closed to new beneficiaries in 2020. The percentage of individual Medigap enrollees relative to non–dually eligible traditional Medicare beneficiaries increased from 2013-2024.
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT
2
Pharmacy, Claims Data Show High Resmetirom Persistence in MASH
3
FDA Approves First Dual-Targeted Therapy for Advanced HNSCC
4
Phase 3 Data Back ALP Normalization as Treatment Goal in PBC
5